• 1
    Rose TM, Bruce AG. Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6. Proc Natl Acad Sci U S A 1991; 88: 86415.
  • 2
    Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997; 40: 10961105.
  • 3
    Cawston TE, Curry VA, Summers CA, Clark IM, Riley GP, Life PF, et al. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum 1998; 41: 176071.
  • 4
    Bell MC, Carroll GJ, Chapman HM, Mills JN, Hui W. Oncostatin M induces leukocyte infiltration and cartilage proteoglycan degradation in vivo in goat joints. Arthritis Rheum 1999; 42: 254351.
  • 5
    Langdon C, Kerr C, Hassen M, Hara T, Arsenault AL, Richards CD. Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. Am J Pathol 2000; 157: 118796.
  • 6
    De Hooge AS, van de Loo FA, Bennink MB, de Jong DS, Arntz OJ, Lubberts E, et al. Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappaB ligand. Am J Pathol 2002; 160: 173343.
  • 7
    Yao L, Pan J, Setiadi H, Patel KD, McEver RP. Interleukin 4 or oncostatin M induces a prolonged increase in P-selectin mRNA and protein in human endothelial cells. J Exp Med 1996; 184: 8192.
  • 8
    Modur V, Feldhaus MJ, Weyrich AS, Jicha DL, Prescott SM, Zimmerman GA, et al. Oncostatin M is a proinflammatory mediator: in vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest 1997; 100: 15868.
  • 9
    Langdon C, Leith J, Smith F, Richards CD. Oncostatin M stimulates monocyte chemoattractant protein-1– and interleukin-1–induced matrix metalloproteinase 1 production by human synovial fibroblasts in vitro. Arthritis Rheum 1997; 40: 213946.
  • 10
    Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A 1986; 83: 874953.
  • 11
    Van de Loo AA, van den Berg WB. Effects of murine recombinant interleukin 1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 1990; 49: 23845.
  • 12
    Cawston TE, Ellis AJ, Humm G, Lean E, Ward D, Curry V. Interleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture. Biochem Biophys Res Commun 1995; 215: 37785.
  • 13
    Hui W, Bell M, Carroll G. Oncostatin M (OSM) stimulates resorption and inhibits synthesis of proteoglycan in porcine articular cartilage explants. Cytokine 1996; 8: 495500.
  • 14
    Manicourt DH, Poilvache P, van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ. Synovial fluid levels of tumor necrosis factor α and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum 2000; 43: 2818.
  • 15
    Van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995; 38: 16472.
  • 16
    Van de Loo FA, Arntz OJ, Otterness IG, van den Berg WB. Protection against cartilage proteoglycan synthesis inhibition by antiinterleukin 1 antibodies in experimental arthritis. J Rheumatol 1992; 19: 34856.
  • 17
    Taskiran D, Stefanovic-Racic M, Georgescu H, Evans C. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun 1994; 200: 1428.
  • 18
    Van de Loo FA, Arntz OJ, van Enckevort FH, van Lent PL, van den Berg WB. Reduced cartilage proteoglycan loss during zymosan-induced gonarthritis in NOS2-deficient mice and in anti–interleukin-1–treated wild-type mice with unabated joint inflammation. Arthritis Rheum 1998; 41: 63446.
  • 19
    Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen–induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti–IL-1α/β, and IL-1Ra. Arthritis Rheum 1996; 39: 797809.
  • 20
    Joosten LA, Helsen MM, Saxne T, van de Loo FA, Heinegard D, van den Berg WB. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999; 163: 504955.
  • 21
    De Hooge AS, van de Loo FA, Arntz OJ, van den Berg WB. Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis. Am J Pathol 2000; 157: 208191.
  • 22
    Malik N, Haugen HS, Modrell B, Shoyab M, Clegg CH. Developmental abnormalities in mice transgenic for bovine oncostatin M. Mol Cell Biol 1995; 15: 234958.
  • 23
    Senac MO Jr, Deutsch D, Bernstein BH, Stanley P, Crues JV III, Stoller DW, et al. MR imaging in juvenile rheumatoid arthritis. AJR Am J Roentgenol 1988; 150: 8738.
  • 24
    Sundberg J, Brattstrom M. Juvenile rheumatoid gonarthritis. II. Disturbance of ossification and growth. Acta Rheumatol Scand 1965; 11: 27990.
  • 25
    White PH. Growth abnormalities in children with juvenile rheumatoid arthritis. Clin Orthop 1990; Oct: 4650.
  • 26
    Yamada H, Mizumo S, Horai R, Iwakura Y, Sugawara I. Protective role of interleukin-1 in mycobacterial infection in IL-1 alpha/beta double-knockout mice. Lab Invest 2000; 80: 75967.
  • 27
    Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368: 33942.
  • 28
    Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996; 184: 13971411.
  • 29
    MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995; 81: 64150.
  • 30
    Kerr C, Langdon C, Graham F, Gauldie J, Hara T, Richards CD. Adenovirus vector expressing mouse oncostatin M induces acute-phase proteins and TIMP-1 expression in vivo in mice. J Interferon Cytokine Res 1999; 19: 11951205.
  • 31
    Schwarzenberger P, La Russa V, Miller A, Ye P, Huang W, Zieske A, et al. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol 1998; 161: 63839.
  • 32
    McLaren DJ, Strath M, Smithers SR. Schistosoma mansoni: evidence that immunity in vaccinated and chronically infected CBA/Ca mice is sensitive to treatment with a monoclonal antibody that depletes cutaneous effector cells. Parasite Immunol 1987; 9: 66782.
  • 33
    Van Meurs JB, van Lent PL, Joosten LA, van der Kraan PM, van den Berg WB. Quantification of mRNA levels in joint capsule and articular cartilage of the murine knee joint by RT-PCR: kinetics of stromelysin and IL-1 mRNA levels during arthritis. Rheumatol Int 1997; 16: 197205.
  • 34
    Joosten LA, Lubberts E, Durez P, Helsen MM, Jacobs MJ, Goldman M, et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40: 24960.
  • 35
    Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25: 19914.
  • 36
    Brown TJ, Rowe JM, Liu JW, Shoyab M. Regulation of IL-6 expression by oncostatin M. J Immunol 1991; 147: 217580.
  • 37
    Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187: 4618.
  • 38
    Campbell IK, O'Donnell K, Lawlor KE, Wicks IP. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest 2001; 107: 151927.
  • 39
    Van den Berg WB. Lessons from animal models of arthritis. Curr Rheumatol Rep 2002; 4: 2329.
  • 40
    Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K, et al. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 1995; 96: 235763.
  • 41
    Presle N, Cipolletta C, Jouzeau JY, Abid A, Netter P, Terlain B. Cartilage protection by nitric oxide synthase inhibitors after intraarticular injection of interleukin-1β in rats. Arthritis Rheum 1999; 42: 2094102.
  • 42
    Van den Berg WB, Joosten LA, Helsen M, van de Loo FA. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994; 95: 23743.
  • 43
    Steinberg JJ, Hubbard JR, Sledge CB. Chondrocyte-mediated breakdown of cartilage. J Rheumatol 1987 May;14 Spec No: 558.
  • 44
    Moore AR, Iwamura H, Larbre JP, Scott DL, Willoughby DA. Cartilage degradation by polymorphonuclear leucocytes: in vitro assessment of the pathogenic mechanisms. Ann Rheum Dis 1993; 52: 2731.
  • 45
    Van Lent PL, van den Hoek AE, van den Bersselaar LA, van de Loo FA, Eykholt HE, Brouwer WF, et al. Early cartilage degradation in cationic immune complex arthritis in mice: relative role of interleukin 1, the polymorphonuclear cell (PMN) and PMN elastase. J Rheumatol 1994; 21: 3219.
  • 46
    Kerfoot SM, Raharjo E, Ho M, Kaur J, Serirom S, McCafferty DM, et al. Exclusive neutrophil recruitment with oncostatin M in a human system. Am J Pathol 2001; 159: 15319.
  • 47
    Van Meurs JB, van Lent PL, Holthuysen AE, Singer II, Bayne EK, van den Berg WB. Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum 1999; 42: 112839.
  • 48
    Resnick D, Sartoris D, Cone RO. Diagnostic tests and procedures in rheumatic disease. In: KelleyWN, HarrisEDJr, RuddyS, SledgeCB, editors. Textbook of rheumatology. Philadelphia: WB Saunders; 1989. p. 650708.
  • 49
    Martel W, Holt JF, Cassidy JT. Roentgenologic manifestations of juvenile rheumatoid arthritis. Am J Roentgenol 1962; 88: 40023.
  • 50
    Evans CH, Ghivizzani SC, Oligino TA, Robbins PD. Future of adenoviruses in the gene therapy of arthritis. Arthritis Res 2001; 3: 1426.
  • 51
    Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-De Roo CJ, Kolls JK, et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001; 167: 100413.
  • 52
    Takacs L, Kovacs EJ, Smith MR, Young HA, Durum SK. Detection of IL-1 alpha and IL-1 beta gene expression by in situ hybridization: tissue localization of IL-1 mRNA in the normal C57BL/6 mouse. J Immunol 1988; 141: 308195.
  • 53
    Horan J, Dean DD, Kieswetter K, Schwartz Z, Boyan BD. Evidence that interleukin-1, but not interleukin-6, affects costochondral chondrocyte proliferation, differentiation, and matrix synthesis through an autocrine pathway. J Bone Miner Res 1996; 11: 111929.
  • 54
    Lepore L, Pennesi M, Saletta S, Perticarari S, Presani G, Prodan M. Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin Exp Rheumatol 1994; 12: 5615.
  • 55
    Bernstein BH, Stobie D, Singsen BH, Koster-King K, Kornreich HK, Hanson V. Growth retardation in juvenile rheumatoid arthritis (JRA). Arthritis Rheum 1977; 20 Suppl 2: 2126.
  • 56
    Simon S, Whiffen J, Shapiro F. Leg-length discrepancies in monoarticular and pauciarticular juvenile rheumatoid arthritis. J Bone Joint Surg Am 1981; 63: 20915.